Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells
- 1 March 2017
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 389, 33-40
Abstract
No abstract availableKeywords
Funding Information
- NIH (CA096613, ES020909)
- DOD (AR110050, BC122992)
- Marlene Harris-Ride Cincinnati
- Department of Radiation Oncology
- Keith Casper, the Department of Otolaryngology
This publication has 50 references indexed in Scilit:
- The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinomaCancer Letters, 2016
- State-of-the-Art and Emerging Treatment Options in the Management of Head and Neck Cancer: News from 2013Oncology, 2014
- Clinical and Molecular Genetics of the Phosphodiesterases (PDEs)Endocrine Reviews, 2013
- Pharmacoeconomic issues in head and neck oncologyCurrent Opinion in Oncology, 2013
- Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell linesOncogene, 2009
- The anti‐EGFR monoclonal antibody blocks cisplatin‐induced activation of EGFR signaling mediated by HB‐EGFFEBS Letters, 2008
- Recent Advances in Head and Neck CancerNew England Journal of Medicine, 2008
- Targeting Apoptosis to Overcome Cisplatin Resistance: A Translational Study in Head and Neck CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Wnt/β-catenin signaling inhibits death receptor-mediated apoptosis and promotes invasive growth of HNSCCCellular Signalling, 2006